1889 results about "Targeted therapy" patented technology

The invention provides a drug target affinity prediction algorithm based on protein three-mode and multi-feature fusion, and the algorithm makes full use of sequence information and two-dimensional and three-dimensional structural features of drugs and proteins, and realizes deep integration of data. The technical innovation point lies in that a multi-modal data fusion mechanism and an advanced graph neural network technology are introduced, and the sensitivity and recognition capability of the model to key biomarkers are enhanced through a dynamic attention mechanism. According to the technical advantage, the method has higher accuracy and stability when processing complex biological data, and compared with the prior art, the generalization ability and the interpretability are remarkably improved. In the aspect of technical maturity, the algorithm has passed multiple rounds of verification and shows good prediction performance and adaptability. The method is simple in operation and wide in market application prospect, can assist in new drug discovery and accelerate the drug design process, can also promote the development of the precision medical field, and particularly has important value in targeted therapy and disease prevention strategy formulation.

The invention relates to the field of traditional Chinese medicine effective component new dosage form pharmaceutical preparations, and discloses an M2 type macrophage membrane coated ROS responsive bionic nano drug delivery system, preparation and application. Mesoporous silica is used as a core to load a traditional Chinese medicine effective component, namely tripterine, and lipid components, namely PEGylated distearoyl phosphatidyl ethanolamine (DSPE-PEG), dioleoyl lecithin (DOPC), cholesterol and the like, are used as raw materials to prepare a ROS-responsive lipid coating, so that ROS-responsive tripterine mesoporous silica is formed. And then realizing bionic fusion with the M2 type macrophage membrane on the outer layer through an ultrasonic coating technology to prepare the M2 type macrophage membrane coated ROS responsive bionic mesoporous silica nano drug delivery system. The invention can realize targeted therapy of rheumatoid arthritis, and has the advantages of biological safety and the like.

The invention relates to the technical field of intelligent medical treatment, and discloses an AI-based severe patient sepsis early warning method and system. According to the method, a multi-organ interaction mechanism is deeply analyzed by dynamically constructing an organ-level causal network, and early-stage accurate early warning of sepsis is realized: high-frequency physiological waveforms, asynchronous laboratory indexes and treatment intervention data are fused, and the capture ability of microcirculation failure and autonomic nerve decline is improved; the early warning threshold value is dynamically adjusted based on the treatment coverage degree, and the delay and false alarm defects of a fixed threshold value mechanism are effectively overcome; a pathogen targeted therapy map and an organ function support scheme are automatically generated by a graded triggered clinical action chain, and the clinical decision response time is shortened; according to the method, the risk of missed diagnosis is reduced while the early warning sensitivity is improved, and an earlier and more reliable intervention window is provided for critical patients.

The invention discloses brain-targeted stem cell membrane bionic cationic liposome as well as a preparation method and application thereof. The preparation method comprises the following steps: extracting and purifying to obtain a stem cell membrane; preparing a cationic liposome; the stem cell membrane and the cationic liposome are fused to obtain the stem cell membrane bionic cationic liposome, and the relative dosage of the stem cell membrane and the cationic liposome is that the mass ratio of the total protein mass of the stem cell membrane to the total fat mass of the cationic liposome is 1: (2-24). The stem cell membrane bionic cationic liposome constructed by using the purified stem cell membrane has high brain targeting ability, low immune irritation and efficient nucleic acid drug carrying ability, can break through the blood brain barrier, realizes efficient targeting delivery of nucleic acid drugs to cells of the brain including neurons, and has good application prospects. Particularly, the polypeptide can be used as a targeted delivery platform of nucleic acid drugs for targeted therapy of cerebral diseases, especially cerebral arterial thrombosis.

The invention discloses an inflammation-targeting bionic extracellular vesicle as well as a preparation method and application thereof, and particularly relates to the field of medicines. According to the invention, a new generation of aminoglycoside antibiotic teicoplanin (Teic), which is high in albumin binding rate and weak in intracellular antibacterial effect, is loaded on neutrophil-derived extracellular vesicles (NEV) with natural drug carrying capacity and inflammatory response chemotactic capacity to prepare the drug-loaded vesicles (Teic-NEV), wherein the new generation of aminoglycoside antibiotic teicoplanin (Teic) is used for loading the neutrophil-derived extracellular vesicles (NEV). The drug-loaded extracellular vesicle Teic-NEV can be used for targeted therapy of cells and tissues infected by MRSA (Methicillin-Resistant Staphylococcus Aureus). In vitro, the Teic (at) NEV can be used for destroying MRSA mature biological membranes and killing intracellular MRSA. According to the invention, the in-vivo and in-vitro biological safety of the TeicatNEV is evaluated. Therefore, the invention provides a certain theoretical basis for the application of NEV-based drug delivery in the field of intracellular bacteria treatment, and also provides a new treatment strategy for in-vivo targeted treatment.

The invention belongs to the technical field of biomedical materials, and relates to ultrasonic response adhesion integrated hydrogel as well as a preparation method and application thereof, the hydrogel comprises a hydrogel matrix, an interface anchoring agent and a functional load component; the preparation method comprises the following steps: 1, preparing a hydrogel precursor solution, and preparing a hydrogel matrix into a solution; 2, carrying out mold molding or injection crosslinking on the solution prepared in the step 1 to form hydrogel; 3, preparing an interface anchoring agent solution, and dissolving or dispersing an interface anchoring agent in a solvent to prepare the interface anchoring agent solution; the ultrasonic responsive adhesive hydrogel platform provided by the invention can provide an efficient, controllable and universal solution for tissue adhesion, targeted therapy, wearable attachment and the like in a complex microenvironment, and is suitable for a plurality of clinical scenes such as chronic wound management, surgical postoperative closure, infection control, adhesive bioelectronic fixation, soft tissue engineering and the like.

The invention discloses a skin targeted therapy laser control method and system based on a dual-wavelength synergistic effect, and the method comprises the steps: collecting the real-time morphological characteristics and pigment distribution data of skin tissues through a multispectral imaging unit, and recognizing the optical characteristic parameters of a target treatment region; generating a dual-wavelength combination scheme through a dynamic wavelength selection algorithm based on the optical characteristic parameters and the tissue structure characteristics of the target treatment area; according to a dual-wavelength combination scheme, generating a synergistic laser sequence with a specific pulse interval and energy ratio; the synergistic laser sequence is converted into a driving signal, and a dual-wavelength laser is controlled to output composite laser; and laser output parameters are dynamically adjusted through real-time thermal diffusion monitoring and an optical feedback mechanism. By utilizing the embodiment of the invention, accurate and selective heat dissipation of skin target tissues can be realized, surrounding normal tissues are effectively protected, the treatment safety and effectiveness are improved, and side effects are reduced.

This disclosure describes a Machine Learning (ML) framework, including graph convolution neural networks (GCN) for identifying gene expression signatures related to cancer driver events. The model is trained to identify the TP53 mutational state of cancer samples from gene expression, utilizing comprehensive curated graph structures of gene interactions. A quantitative score is generated to rank the severity of a driver event in each sample. Very high AUG results on unseen data across several tumor types are achieved with this method. There is a strong correlation with protein function. The Signatures in Transcriptome Associated with Mutated Protein (STAMP) model can also predict driver events in many combinations of important cancer genes / pathways and several tumor types, based on well-established annotations from the literature. The STAMP model therefore can identify and quantify driver events, which may lead the way to improved targeted therapy selection and prioritization in cancer patients.

The invention belongs to the technical field of chemistry, and particularly relates to a diaryl methyl pyrimidine piperazine compound as well as a preparation method, a pharmaceutical composition and application thereof. The structural formula of the diaryl methyl pyrimidine piperazine compound is shown as a formula I, and R is a substituted aromatic group. The preparation process is simple, the prepared diaryl methyl pyrimidine piperazine compound or the pharmaceutically acceptable salt thereof has the activity of efficiently inhibiting WDR5-MLL 1, and a targeted therapy scheme and novel, safe and efficient candidate drug molecules are provided for treating acute myeloid leukemia with WDR5-MLL fusion mutation. Experimental results show that the tumor inhibition rates of mouse tumor-bearing groups treated by the compounds 5c, 5k and 5l prepared by the invention are 79%, 85% and 75% respectively and are superior to those of a positive control group, and the compounds have good development prospects.

The invention discloses an application of a therapeutic target spot in preparation of a drug for treating targeted therapy resistance of kidney cancer. The therapeutic target spot is SLC27A3. The SLC27A3 comprises an SLC27A3 gene and a coding sequence thereof, an expression product of the SLC27A3 gene and a coding sequence thereof, and the SLC27A3 gene and an active fragment or derivative of the expression product thereof; the nucleotide of the SLC27A3 is as shown in SEQ ID NO. 1. According to the invention, a therapeutic target SLC27A3 is knocked out or silenced, and a compound Parishin for resisting the SLC27A3 protein is provided, so that the resistance of renal clear cell carcinoma cells to the pezopanib is remarkably improved, and the sensitivity of renal carcinoma cells to the pezopanib is enhanced.

The invention discloses a method for constructing a Ddx58-R109C point mutation mouse model by using a CRISPR / Cas9 gene editing technology and an application of the Ddx58-R109C point mutation mouse model. The method comprises the following steps: (1) target construction: searching a CDS region of a Ddx58 gene, determining an exon part, and determining a gene mutation site; (2) obtaining a fertilized egg, and injecting Cas9mRNA, gRNA and donor oligo into the fertilized egg of the C57BL / 6J mouse together in vitro through a microinjection technology to obtain an F0-generation hybrid mouse; (3) mating the F0-generation hybrid mouse with the wild type mouse to obtain an F1-generation mouse; (4) the F1-generation heterozygous mice which are identified to be positive are subjected to mating, and homozygous Ddx58-R109C mutant type and wild type mice can be obtained by breeding obtained offspring; (5) phenotypic analysis shows that Ddx58-R109C point mutation mice can have pathological changes of systemic lupus erythematosus and lupus nephritis; the invention can provide an effective research approach and method for researchers to deeply explore the action mechanism of Ddx58-R109C mutation in diseases, and has important significance for explaining the pathogenesis of systemic lupus erythematosus and researching and developing targeted therapeutic drugs.

The invention discloses a method for identifying the effectiveness of a Cas target spot by combining a gene large model and ML, and belongs to the field of biotechnology and artificial intelligence. The method comprises the following steps: constructing a detection array of A types of combined sequences and targeted combined sequences, wherein the detection array is provided with A detection units; respectively adding a combined sequence into each detection unit, carrying out incubation reaction, obtaining a fluorescence value of each detection unit, and carrying out normalization processing; carrying out key feature extraction on each combined sequence by adopting a feature extraction model; constructing a label set and a training set, constructing an integrated model, and training by adopting the label set and the training set; forming a machine learning model by the feature extraction model and the trained integrated model; and combining the new target sequence and the PAM sequence into a to-be-analyzed combined sequence, inputting the to-be-analyzed combined sequence into the machine learning model to obtain a predicted fluorescence value, and judging the recognition capability of the Cas protein on the combined sequence based on the fluorescence value. The method can assist in targeted therapy detection.

The invention relates to the field of biological medicine, in particular to elastin-like polypeptide as well as a preparation method and application thereof. The amino acid sequence of the elastin-like polypeptide is (VPGXG) n, X comprises I, A and F, and n is an integer selected from 20-120. The elastin-like polypeptide disclosed by the invention has reversible phase change temperature, a purification method is simple, and the elastin-like polypeptide has good and controllable release capacity. The elastin-like polypeptide disclosed by the invention can serve as a drug storage cavern, can be coupled with various drugs, and can improve the treatment effect of the carried drugs, so that targeted therapy is more accurate.

This application provides methods and compositions related to real time monitoring targeted therapeutics by measuring time-dependent dynamics in distinct subpopulations of secreted vesicles. The technology utilizes bio-orthogonal probe amplification and spatial patterning of molecular reactions within plasmonic resonators to measure EV drug dynamics directly in patient blood samples. Small-molecule click probes are used in the assays for competitive, in situ target labeling in whole vesicles; the labeling of target by the probes can be enzymatically amplified to detect drug occupancy in EVs.

The invention belongs to the technical field of organic synthesis, and particularly discloses an ammonia aromatic alkene modified near-infrared BODIPY fluorescent probe as well as a preparation method and application thereof.The near-infrared BODIPY fluorescent probe is obtained by adopting 6-(dimethylamino) nicotinic aldehyde to directionally modify the alpha position of BODIPY and constructing an expanded conjugated system through Knoevenagel condensation. Wherein dimethylamino provides a strong electron donating effect, a molecular structure is twisted into a non-planar configuration due to steric hindrance of a pyridine ring, pi-pi accumulation is reduced, and an ACQ effect is inhibited. According to the structural modification strategy, significant red shift of absorption / emission wavelength is realized by expanding a molecular pi-conjugated skeleton, and meanwhile, the stability of the BODIPY core and the quantum yield are effectively enhanced. The probe molecule can specifically recognize the diphenylalanine dipeptide structural unit by utilizing the synergistic coordination effect of the 2-aminopyridine derivative and the BODIPY mother nucleus, so that the selective detection of the Alzheimer's disease biomarker Abeta42 is realized, and a novel optical detection tool is provided for the early molecular diagnosis and targeted therapy of AD (Alzheimer's disease).

The invention relates to the field of molecular targeted therapy, and discloses an application of an SLC16A5 (MCT6) small-molecule inhibitor MCT6-Ai7-2 in preparation of a medicine for treating acute myeloid leukemia (AML). The inhibitor takes an SLC16A5 protein structure predicted by Alphafold as a target spot, and is obtained through compound database screening, molecular docking and druggability optimization. An in-vitro experiment proves that MCT6-Ai7-2 can remarkably inhibit proliferation of AML cell lines such as U937 and MOLM-13, induce cell apoptosis and retard a cell cycle, has an inhibiting effect on a primary AML patient specimen and is relatively low in toxicity to normal cells; in-vivo experiments show that the compound is effective and has good safety in AML model mice. In addition, the MCT6-Ai7-2 and the vinca can be combined to synergistically enhance the inhibition effect on vinca drug-resistant cells, and by reducing the expression of anti-apoptotic protein MCL-1, the activation of pro-apoptotic factors BIM and tBID is promoted to play a role. The invention provides a novel targeting drug and strategy for treatment of AML (especially drug-resistant or recurrent patients).

Provided is a recombinant human serum albumin-collagen binding domain (CBD) fusion protein for tumor-specific targeting matrix and its use in specific targeted treatment of a solid tumor. HSA and the CBD generate gene fusion in the form of different molecular structures, and can be expressed in a constructed recombinant engineered host. A pharmaceutical recombinant fusion protein is obtained through large-scale fermentation. The recombinant fusion protein shows tumor-specific targeting of solid tumors and can be used as a starting material of a broad-spectrum matrix carrier. The recombinant fusion protein is coupled with any tumor treatment drug, small-molecule compound, or cytotoxic protein to form an innovative pharmaceutical composition. The pharmaceutical composition of the recombinant fusion protein is also long-acting, can prolong a half-life of the conjugate drug in vivo, and has a significantly better clinical curative efficacy on anti-tumor than that of a monomer drug.

The invention belongs to the technical field of nuclear medicine molecular diagnosis and treatment, and discloses a modified CAIX targeting cyclic peptide, a nuclide marker and application of the modified CAIX targeting cyclic peptide in tumor diagnosis and treatment. According to the CAIX targeted cyclic peptide, a rigid bifunctional chelating agent RESCA is introduced to replace a traditional chelating agent, and a sulfonated or alkylated amino acid connector is combined, so that the enzymolysis resistance and in-vivo stability of the probe are remarkably improved. By optimizing the structure of the connector, the lipophilicity is reduced, liver and gall metabolism and non-specific uptake are reduced, and the high uptake rate of tumor target tissues is maintained. The therapeutic nuclide marker of the cyclopeptide can be used for intratumoral irradiation therapy using DOTA or NOTA in combination with an alkylated amino acid linker or an albumin ligand. Experiments show that the marker has high radiochemical purity, excellent pharmacokinetic characteristics and low kidney retention, and is suitable for precise diagnosis and targeted therapy of CAIX high expression tumors such as kidney cancer, colorectal cancer and brain glioma.

Disclosed are methods of treating a subject with a neurological disease associated with a splicing defect caused by TDP-43 proteinopathies, comprising administering to said subject an agent to increase expression levels and / or stability of hnRNP L, thereby attenuating and / or repairing the splicing defect. The disclosure also relates to nucleic acids targeting heterogeneous nuclear ribonucleoprotein L (hnRNP L), and their use.

The invention provides an ergosterol-loaded brain-targeted nano preparation and a preparation method and application thereof, and relates to the field of nano materials and nano biological medicine.The active ingredient ergosterol of the nano preparation is entrapped in a DSPE-PEG-pinacol borate nano material, and the nano material has the ROS response characteristic and can be used for preparing a brain-targeted nano preparation. The ergosterol-loaded nano preparation is in the shape of a regular sphere, is uniform in particle size, has good dispersibility and stability, has good ability of targeted therapy of cerebral arterial thrombosis diseases, effectively solves the problems of poor targeting property, low bioavailability and the like of common drugs, enhances the therapeutic effect of ergosterol on cerebral arterial thrombosis, and has good application prospects. The ergosterol can effectively improve brain injury caused by the cerebral arterial thrombosis and has a good treatment effect, meanwhile, the ergosterol serving as the active ingredient plays a role in treating the cerebral arterial thrombosis by activating a PI3K / AKT / mTOR pathway, and a new direction is provided for treatment of the cerebral arterial thrombosis.

The present invention relates to a novel anoctamin 1 (ANO1) inhibitory compound and has been completed by confirming that the novel compound may inhibit brain tumor by inhibiting the expression or activity of ANO1 which is a calcium-dependent chloride channel. Thus, according to the present invention, a novel compound usable as an ANO1 inhibitor may be provided. In addition, the compound of the present invention may simultaneously inhibit ANO1 and EGFR in brain tumor cells, and thus may be used as a dual-target anticancer agent for ANO1 and EGFR, and may also be used as a combined preparation for EGFR-targeted therapy, and thus is expected to be usable in various ways in the field of brain tumor prevention and treatment.

The invention provides an engineered membrane coated nano drug delivery system and application thereof, and belongs to the technical field of nano biomedices.The drug delivery system comprises an inner core combined with a drug, the inner core is coated with a cell membrane, based on the nano drug loading technology and the membrane coating technology, DOX and SRF are loaded on mPDA mesoporous nanoparticles, and thyroid cancer synergistic killing nanoparticles mPDS are formed; the bionic drug delivery system is characterized in that mPDS is used as a target drug delivery system, mPDS is coated with a genetically engineered tumor cell membrane, a dual-targeting membrane-coated nano drug delivery system (mPDS-coated CAR-M) is obtained, and the bionic drug delivery system can penetrate through thyroid cancer in a targeted manner, gather in a focus and reduce side effects of chemotherapy; when near-infrared irradiation is carried out on local tumor, DOX and SRF in mPDS are released, the synergistic effect of photothermal therapy-chemotherapy-targeted therapy is achieved, and the thyroid cancer is killed synergistically.

Provided is the use of OXCT1 protein as succinyltransferase. It has been found that the OXCT1 protein serving as succinyltransferase can promote the growth of cancer cells by modulating succinylation modification of protein. Therefore, the design of related enzyme inhibitors can inhibit the activity of succinyltransferase, thereby inhibiting the occurrence and progression of cancer, thereby providing a new concept for targeted therapy.

The invention discloses a leukemia targeted therapy preparation as well as a preparation method and application thereof. Comprising a DNA nanoflower carrier targeting leukemia cells through a PTK7 receptor and benzene arsenic oxide loaded on the carrier. The DNA nanoflower carrier is obtained by rolling circle amplification, and a nucleic acid aptamer complementary sequence of targeted binding leukemia cells is introduced into a template chain subjected to rolling circle amplification. The preparation method comprises the following steps: modifying sulfydryl onto a DNA nanoflower by using DNA-Dithiol, then breaking a disulfide bond by using reduced glutathione to expose the sulfydryl, and loading benzene arsenic oxide onto the DNA nanoflower through a reaction between trivalent arsenic and the sulfydryl. The structure of the DNA nanoflower has a high surface area and high porosity, and can load a large amount of PAO, so that the killing performance on cancer cells is enhanced; the aptamer sgc8 sequence is introduced into the DNA nanoflower, so that the targeting of the DNA nanoflower to cancer cells is effectively realized; the preparation also has the advantages of being good in thermodynamic stability, easy to store, excellent in biocompatibility and the like, and has a very good application prospect.

The invention provides a biological material for repairing an ovarian function as well as a preparation method and application thereof, and relates to the technical field of biological materials, a large number of experiments prove that specific biological protein components for reversing the ovarian function in extracellular vesicles are growth differentiation factor 9 (GDF-9) for repairing an ovary, and the biological material has the advantages that the ovarian repairing function mechanism of the specific biological protein components for reversing the ovarian function in the extracellular vesicles is found; according to the present invention, the GDF-9 extracellular vesicles (GDF-9Over-existed Extracellular vesicles, GOEs) are adopted as the active substance, such that the component is effectively extracted and purified so as to achieve the target of targeted therapy.

The invention relates to an application of a compound DB07268 in preparation of a RAGAP1 inhibitor. Candidate compounds possibly interacting with RACGAP1 protein are screened out through large-scale virtual docking and CCK8 experiments and verified through SPR experiments, the compound DB07268 with the highest affinity with RACGAP1 is further screened out, and finally the acting effect of the compound DB07268 is verified through cell experiments and molecular experiments. Compared with the prior art, the invention discovers that DB07268 can be used as the RACGAP1 inhibitor for targeted therapy of RACGAP1 related diseases, such as various tumors, diabetic nephropathy, acute kidney injury, congenital heart disease, congenital erythropoiesis abnormality anemia, virus infectious diseases and the like.

The invention discloses a neutralizing nucleic acid aptamer for targeted inhibition of a B cell activating factor and application of the neutralizing nucleic acid aptamer in treatment of systemic lupus erythematosus. The neutralizing aptamer disclosed by the invention can be used for efficiently inhibiting the combination of BAFF and specific receptors on a B cell membrane, including a BAFF receptor (BAFF-R), a human calcium regulatory cyclophilin ligand interaction molecule (TACI) and a B cell maturation antigen (BCMA), so that the proportion of plasma cells, plasma mother cells and hair growth center B cells is reduced, and finally, the generation and secretion of autoantibodies are reduced; the compound has a targeted therapeutic effect on systemic lupus erythematosus. Compared with an existing biological agent for neutralizing BAFF, the neutralizing nucleic acid aptamer has the advantages of being high in specificity, high in affinity, easy to synthesize, low in immunogenicity, low in cost, capable of being designed and programmed and the like, is a potential novel nucleic acid preparation for SLE targeted therapy, and has a good clinical transformation application prospect.

The invention discloses a mesenchymal stem cell membrane bionic nano-enzyme for targeted therapy of Parkinson's disease as well as a preparation method and application of the mesenchymal stem cell membrane bionic nano-enzyme. The mesenchymal stem cell membrane bionic nano enzyme comprises an inner core and a mesenchymal stem cell membrane, wherein the inner core is composed of mesoporous polydopamine nanoparticles, and the mesenchymal stem cell membrane coats the inner core. The medicine contains the mesenchymal stem cell membrane bionic nano enzyme. The mesenchymal stem cell membrane bionic nano-enzyme disclosed by the invention shows good biocompatibility, and can be homed to a Parkinson disease region in the brain under the mediation of CXCR4 and VLA-4 specific membrane proteins. In addition, through the CD47 membrane protein expressed on the surface, the removal of the immune system can be avoided, so that the action time in the body is prolonged. The nano-enzyme is helpful for eliminating reactive oxygen free radicals, reducing oxidative stress level and reducing damage of neuroinflammation to dopaminergic neurons, so that safe and efficient treatment of Parkinson's disease is realized.

The invention discloses an oral monoclonal antibody micro-coated nanopolysaccharide microsphere preparation for targeted therapy of inflammatory bowel diseases and a preparation method thereof. According to the method, oxidized mannan and an anti-TNF-alpha monoclonal antibody are mixed and cross-linked by a cross-linking agent containing a diselenide bond to form the drug-loaded nanoparticles. Mixing the drug-loaded nanoparticles with pectin, dropwise adding the mixture into a calcium chloride solution through an electrostatic spinning device, and carrying out ionic crosslinking to obtain the oral monoclonal antibody micro-coated nano polysaccharide microsphere preparation with the particle size range of 180-200 microns. The drug-loaded polysaccharide microsphere delivers the wrapped drug-loaded nanoparticles to a colitis disease part through electrostatic interaction. The drug-loaded nanoparticles are targeted to macrophages, release of the monoclonal antibody is accelerated under the triggering of high-concentration active oxygen at an inflammation part, and the oral stability and the treatment effect of the monoclonal antibody drug are improved. The polysaccharide is used as a monoclonal antibody targeted delivery carrier, raw materials are cheap and easy to obtain, the preparation process is simple and convenient, reaction conditions are mild, and application and development are easy.

The invention discloses a dual-targeting bionic liposome composite material and a preparation method and application thereof, and belongs to the technical field of nano-medices.The dual-targeting bionic liposome composite material is prepared by taking liposome nano-particles as a carrier, loading iloumab and alkannin on the carrier to obtain drug-loaded liposome, and fusing the drug-loaded liposome with a macrophage membrane to obtain the dual-targeting bionic liposome composite material. And modifying with phospholipidic hyaluronic acid to obtain the double-targeting bionic liposome composite material. According to the invention, two anti-atherosclerosis effects with different mechanisms, i.e., lipid lowering by Elolukumab and anti-inflammation by alkannin, are utilized to realize targeted therapy of atherosclerosis, and the bionic membrane on the outermost layer realizes long blood circulation and lesion site targeting ability of the composite material through inherent immune escape and recruitment characteristics of macrophages. The characteristic that hyaluronic acid interacts with a target cell surface receptor CD44 is utilized, effective utilization of the target cell on the composite material is achieved, and the atherosclerosis prevention and treatment effect of the composite material is improved.